scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1031099363 |
P356 | DOI | 10.1007/S10096-014-2192-X |
P698 | PubMed publication ID | 25070493 |
P2093 | author name string | I Nakamura | |
T Yamaguchi | |||
A Sato | |||
S Fukushima | |||
T Matsumoto | |||
A Tsukimori | |||
P2860 | cites work | IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate | Q34939154 |
Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections | Q36095874 | ||
Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli. | Q39470560 | ||
Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a 'break-point checkerboard plate'. | Q43225854 | ||
In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa | Q44636897 | ||
Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. | Q45981762 | ||
Effectiveness of antibiotic combination therapy as evaluated by the Break-point Checkerboard Plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use. | Q50726914 | ||
The fractional inhibitory concentration (FIC) index as a measure of synergy | Q71796362 | ||
Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus | Q73328444 | ||
Use of Parenteral Colistin for the Treatment of Serious Infection Due to Antimicrobial-Resistant Pseudomonas aeruginosa | Q79291069 | ||
In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan | Q83317700 | ||
'Break-point Checkerboard Plate' for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa | Q83366970 | ||
P433 | issue | 1 | |
P921 | main subject | Pseudomonas aeruginosa | Q31856 |
multiple drug resistance | Q643839 | ||
P304 | page(s) | 83-87 | |
P577 | publication date | 2014-07-29 | |
P1433 | published in | European Journal of Clinical Microbiology & Infectious Diseases | Q15754378 |
P1476 | title | New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa | |
P478 | volume | 34 |
Q40675239 | Arbekacin activity against contemporary clinical bacteria isolated from patients hospitalized with pneumonia |
Q26751041 | Clinical Usefulness of Arbekacin |
Q36409828 | Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa |
Q41240109 | In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. |
Q40412684 | Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections. |
Search more.